TMDX
TMDX
US89377M1099
TransMedics Group, Inc.
Loading chart...

Company Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Latest News

Related stocks

NEOG
NEOG • United States
Neogen Corporation
11.85 USD
2.59B USD 1Y +101.2%
BFLY
BFLY • United States
Butterfly Network, Inc.
8.25 USD
2.2B USD 1Y +199.6%
ALMR
ALMR • United States
Alamar Biosciences, Inc.
25.27 USD
1.75B USD
IRTC
IRTC • United States
iRhythm Holdings, Inc.
106.7 USD
3.52B USD 1Y -42.7%
LMRI
LMRI • United States
Lumexa Imaging Holdings, Inc.
10.54 USD
1.01B USD
BBNX
BBNX • United States
Beta Bionics, Inc.
17.63 USD
951.07M USD 1Y -21.2%
CBLL
CBLL • United States
CeriBell, Inc.
23.63 USD
906.87M USD 1Y +89.1%
TNDM
TNDM • United States
Tandem Diabetes Care, Inc.
16.11 USD
1.12B USD 1Y +2.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
71.4% p.a.
Max Drawdown (5Y)
-67.8%
Sharpe Ratio (5Y)
0.30
Beta Factor
1.93
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
High market risk: Beta of 1.93 indicates above-average volatility compared to the broader market.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (71.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -67.8% in the extended horizon.
ende